We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Brazilian government's startling decision to end its threat to break patents
on Abbott Laboratories' HIV/AIDS drug Kaletra has won international praise.
AstraZeneca PLC and US group Avanir Pharmaceuticals have agreed to jointly investigate
compounds that could yield treatments for the reversal of heart disease.
Macrocyclics Inc., a University of Texas at Dallas spinoff that produces chemical
compounds used in pharmaceutical and academic research, has inked an R&D
collaboration deal with MDS Nordion, an Ottawa, Canada, provider of products
and services for drug development and laboratory testing.
Drug developer Accentia Biopharmaceuticals Inc. filed with regulators on Monday
to cut the expected price of its planned initial public offering to $8 to $10
per share, from $11 to $13 per share.
GlaxoSmithKline has decided to exercise its option to jointly develop and commercialize
an experimental arthritis treatment with Human Genome Sciences.
Oxford BioMedica, the leading gene therapy company, announced that the Patent
Office of the Peoples' Republic of China has granted two patents to the Company
that have broad claims covering vectors derived from lentiviruses.
India's largest pharmaceutical company is expanding into Canada and mulling
investments in Ontario's biotechnology sector, moves the province hopes will
attract more money and jobs to a key growth market. Ranbaxy Pharmaceuticals,
which had $1 billion US in global sales last year, is establishing its first
Canadian sales office in Mississauga, Ont. It's the first time a pharmaceutical
company from India has set up shop on Canadian soil.